Söndag 22 December | 07:21:54 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2026-02-26 07:00 Bokslutskommuniké 2025
2025-11-20 07:00 Kvartalsrapport 2025-Q3
2025-08-21 07:00 Kvartalsrapport 2025-Q2
2025-05-20 07:00 Kvartalsrapport 2025-Q1
2025-04-15 N/A Årsstämma
2025-02-27 07:00 Bokslutskommuniké 2024
2024-11-18 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-17 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2024-04-16 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-04-13 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2023-04-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-24 - Kvartalsrapport 2022-Q1
2022-04-13 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2022-04-12 - Årsstämma
2022-02-22 - Bokslutskommuniké 2021
2021-11-25 - Kvartalsrapport 2021-Q3
2021-11-17 - Extra Bolagsstämma 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-05-27 - Kvartalsrapport 2021-Q1
2021-04-07 - X-dag ordinarie utdelning NANOFH 0.00 EUR
2021-04-06 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-09-01 - Extra Bolagsstämma 2020
2020-08-28 - Kvartalsrapport 2020-Q2

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nanoform Finland är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av tekniska produkter som används för att skapa nanopartiklar i läkemedel. Tekniken används som komplement i produktionsprocessen och används för behandling av sjukdomar som ALS och Alzheimers. Kunderna består av aktörer inom den globala läkemedelsindustrin. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingfors.
2023-12-05 17:00:00

Company release

Nanoform Finland Plc

December 5, 2023

18.00 Finnish time / 17.00 Swedish time

Share subscriptions based on Nanoform Finland Plc's stock options 1/2019 and 2/2019

A total of 4,000 Nanoform Finland Plc's (the "Company" or "Nanoform") new shares has been subscribed for with the Company's stock options 1/2019 and 2/2019 by 28 November 2023. The entire subscription price for subscriptions made with the stock options of EUR 6,050,00 will be entered in the Company's reserve for invested unrestricted equity.

After the trade registration the total amount of shares is 78,433,964.

The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about 18 December 2023, as of which date the new shares will establish shareholder rights.

The shares will be traded on the NASDAQ Helsinki Plc's First North Growth Market Finland marketplace together with the old shares on or about 19 December 2023.

For further information, please contact:

Peter Hänninen

General Counsel

peter.hanninen@nanoform.com

+358 50 353 0408

For investor relations queries, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.